(redirected from chronic lymphocytic leukemia)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.


Fifth letter of a Nasdaq stock symbol specifying that it is the third preferred bond of the company.


1. On a stock transaction table, a symbol indicating that a dividend was paid after a stock split.

2. A symbol appearing next to a bond listed on NASDAQ indicating that the bond is a company's third preferred bond. All NASDAQ listings use a four-letter abbreviation; if the letter "I" follows the abbreviation, this indicates that the security being traded is a third preferred bond.


Used in the dividend column of stock transaction tables to indicate that the dividend was paid after a stock dividend or split: Lehigh s.20i.
Mentioned in ?
References in periodicals archive ?
Coverage of the B-Cell Chronic Lymphocytic Leukemia pipeline on the basis of route of administration and molecule type.
The report reviews key players involved Refractory Chronic Lymphocytic Leukemia (CLL) therapeutics and enlists all their major and minor projects
A review of the Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
The report provides a snapshot of the global therapeutic landscape of Relapsed Chronic Lymphocytic Leukemia (CLL)
The company said the randomized, multi-centre, open-label Phase III RESONATETM-2 (PCYC-1115) trial assessed the use of IMBRUVICA (ibrutinib) versus chlorambucil in treatment-naive chronic lymphocytic leukemia (CLL) patients aged 65 years or older.
The report provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia
This year, it is expected that there will be approximately 5,000 deaths from Chronic Lymphocytic Leukemia in the United States.
This report provides information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with latest updates, and special features on late-stage and discontinued projects.
Global Markets Direct's, 'B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2016', provides an overview of the B-Cell Chronic Lymphocytic Leukemia pipeline landscape.

Full browser ?